Aclarion Announces $2.5 Million Share Repurchase Program

Aclarion, Inc. (ACON) announced on Wednesday that its board of directors has authorized a share repurchase program totaling up to $2.5 million. The company plans to execute the buyback drive over the next 12 months, utilizing a flexible and opportunistic approach to acquire shares. CEO Brent Ness stated that the company believes its shares currently represent a compelling value. According to Ness, the program is designed to return value to shareholders while the company simultaneously continues to invest in the clinical adoption and expansion of its Nociscan technology. The company confirmed that the repurchase program will be funded using existing cash and cash equivalents available on its balance sheet. This ensures that the buyback does not require new debt issuance or external financing. From a market perspective, share repurchases are generally viewed as a signal of management's confidence in the company's future prospects and an indication that the stock is undervalued. While the $2.5 million cap is modest, it demonstrates a commitment to capital management and shareholder returns during the company's growth phase in the healthcare technology sector.